You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, November 2014
|
| DOI | 10.1186/2051-1426-2-s3-p263 |
| Authors |
Robert HI Andtbacka, Frances A Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith Delman, Lynn Spitler, Igor Puzanov, Sanjiv Agarwala, Mohammed Milhem, Kevin Harrington, Mark Middleton, Ai Li, Mark Shilkrut, Robert Coffin, Howard Kaufman |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 43 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 12% |
| Student > Doctoral Student | 3 | 7% |
| Student > Master | 3 | 7% |
| Student > Postgraduate | 2 | 5% |
| Student > Bachelor | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 28 | 65% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 21% |
| Immunology and Microbiology | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 2% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 28 | 65% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2015.
All research outputs
#2,485,726
of 25,374,917 outputs
Outputs from Journal for Immunotherapy of Cancer
#674
of 3,421 outputs
Outputs of similar age
#28,533
of 276,328 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#4
of 68 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,328 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.